Last reviewed · How we verify
Sovateltide along with standard treatment
At a glance
| Generic name | Sovateltide along with standard treatment |
|---|---|
| Also known as | PMZ-1620 |
| Sponsor | Pharmazz, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy (PHASE2)
- PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury (PHASE2)
- PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients (PHASE2)
- Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke (PHASE3)
- PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sovateltide along with standard treatment CI brief — competitive landscape report
- Sovateltide along with standard treatment updates RSS · CI watch RSS
- Pharmazz, Inc. portfolio CI